Peptide epitopes of VEGFR-2/KDR that inhibit angiogenesis
AssigneeThe Gov. of the USA as represented by the Secretary of the Dept. of Health & Human Services
InventorsSamir Khleif, Yujun Dong
Life of this patent
Estimating the term…
Abstract
The disclosure provides antigenic peptides of Vascular Endothelial Growth Factor Receptor 2(VEGFR-2)/KDR. Pharmaceutical compositions including the peptides and/or antigen presenting cells that exhibit the VEGFR-2/KDR peptides on their cell surface are also provided. Methods for eliciting an immune response and for inhibiting angiogenesis by administering such pharmaceutical compositions are provided.
Claims31
An isolated or synthetic peptide that binds to a Major Histocompatibility (MHC) Class I molecule comprising a subsequence of a Vascular Endothelial Growth Factor Receptor 2 (VEGFR-2).
A pharmaceutical composition comprising:
- (a) at least one isolated or synthetic peptide that binds to a Major Histocompatibility (MHC) Class I molecule comprising a subsequence of a Vascular Endothelial Growth Factor Receptor 2 (VEGFR-2);
- or
- b) an isolated antigen presenting cell (APC) that presents the at least one peptide of (a) on a cell surface MHC Class I molecule;
- and
- a pharmaceutically acceptable carrier.
Dependencies are inferred from the claim text.